CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mediscience Planning, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mediscience Planning, Inc.
Nomura Fudosan Higashi-Nihombashi Bldg.
1-1-7, Higashi-Nihombashi
Phone: +81 358207071p:+81 358207071 CHUO-KU, TKY  103-0004  Japan Fax: +81 358207607f:+81 358207607
This company is no longer actively traded on any major stock exchange.
Business Summary
Mediscience Planning, Inc. is mainly engaged in the development support of pharmaceuticals. The Monitoring segment is engaged in the investigation of clinical trial implementation, the monitoring and confirmation of the implementation, and others. The Data Management segment is engaged in the record, management and analysis of data collected in clinical trials, and the evaluation and discussion of the effectiveness and safety of pharmaceuticals. The Pharmacovigilance segment is involved in the collection, evaluation and analysis of safety information generated in clinical trial, post-marketing clinical trial and post-marketing investigation, and the support for creation of reports to authorities. The Contract Sales Organization (CSO) segment is engaged in the specified dispatching of medical representatives (MRs). The Others segment is engaged in the medical writing, consulting and other businesses. On February 13, 2014, it delisted from the Tokyo Stock Exchange.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
11/30/20138/31/2013Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8999 Services, not elsewhere classified
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, President, Representative Director AkinoriUrae 55 11/25/2011 2/1/2005
Vice President, Senior Executive Officer, Chief Director of Clinical Development, Director MasahiroHoshida 56 11/27/2013 11/26/2009
Senior Managing Director, Senior Executive Officer, Chief Director of Business Administration, Dire MikioNomata 60 12/1/2013 11/26/2009
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 748 (As of 8/31/2013)
Outstanding Shares: 2,547,600 (As of 11/30/2013)
Shareholders: 1,058
Stock Exchange: TYO
Fax Number: +81 358207607


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023